biogen_austria_238

EMA recommends Biogen’s MS treatment Zinbryta

pharmafile | May 3, 2016 | News story | Research and Development, Sales and Marketing Biogen, CHMP, EMA, daclizumab, zinbryta 

The Committee for Medicinal Products for Human Use (CMHP) has recommended the granting of a marketing authorisation for Zinbryta (daclizumab) for the treatment of relapsing forms of multiple sclerosis.

Developed by Biogen, Zinbryta is a humanised IgG1 monoclonal antibody that demonstrated statistical significance in the reduction of annualised relapse rate of multiple sclerosis in the DECIDE Phase III trial. In the same trial, a reduction in the number of new or newly enlarging T2-hyperintense lesions was also observed.

The full indication from the European Medicines Agency is: “Zinbryta is indicated in adult patients for the treatment of relapsing forms of multiple sclerosis.” The marketing authorisation from the European Commission is expected to be ratified following the EMA’s recommendation.

Sean Murray

Related Content

CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

EC approves Pfizer’s Prevenar 20 to protect paediatric patients against pneumococcal disease

Pfizer has announced that the European Commission (EC) has granted marketing authorisation for Prevenar 20, …

louis-reed-pwckf7l4-no-unsplash_5

EMA validates two applications for datopotamab deruxtecan for cancer treatments

AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications …

Latest content